Patents by Inventor Atsuo KANNO

Atsuo KANNO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HUMAN NR1 ANTIBODY DERIVATIVE
    Publication number: 20230220070
    Abstract: The present invention addresses the problem of providing a novel therapeutic agent for treating patients with anti NMDAR encephalitis. Patients with an anti NMDAR encephalitis have a pathogenic anti-human NR1 antibody that induces internalization of NMDAR on cell surface. As a result, NMDAR function is weakened in the patients' brain. The present inventors found that the one-armed anti-human NR1 antibody according to the present invention binds to NR1 competitively with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody to thereby exhibit therapeutic effect on anti NMDAR encephalitis.
    Type: Application
    Filed: November 17, 2022
    Publication date: July 13, 2023
    Inventors: Satoshi KUBO, Atsuo KANNO, Daisuke YAMAJUKU, Takuya KITO, Masashi MAEDA, Takuma MIHARA
  • ANTI-HUMAN TLR7 ANTIBODY
    Publication number: 20230212306
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Application
    Filed: December 27, 2022
    Publication date: July 6, 2023
    Applicants: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Anti-human TLR7 antibody
    Patent number: 11578138
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: February 14, 2023
    Assignees: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • ANTI-HUMAN TLR7 ANTIBODY
    Publication number: 20210332149
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Applicants: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Anti-human TLR7 antibody
    Patent number: 11091560
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: August 17, 2021
    Assignees: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • ANTI-HUMAN TLR7 ANTIBODY
    Publication number: 20210040225
    Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.
    Type: Application
    Filed: October 13, 2020
    Publication date: February 11, 2021
    Applicants: Daiichi Sankyo Company, Limited, The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
  • Preventive or therapeutic agent for inflammatory disease
    Patent number: 10370451
    Abstract: An object of the present invention is to provide a highly-safe and highly-specific preventive or therapeutic agent for inflammatory diseases targeting a TLR7 or TLR9 molecule. The present invention provides a preventive or therapeutic agent for inflammatory diseases containing an anti-TLR7 antibody or anti-TLR9 antibody.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: August 6, 2019
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Kensuke Miyake, Atsuo Kanno, Yuji Motoi, Masahiro Onji
  • PREVENTIVE OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE
    Publication number: 20160185871
    Abstract: An object of the present invention is to provide a highly-safe and highly-specific preventive or therapeutic agent for inflammatory diseases targeting a TLR7 or TLR9 molecule. The present invention provides a preventive or therapeutic agent for inflammatory diseases containing an anti-TLR7 antibody or anti-TLR9 antibody.
    Type: Application
    Filed: October 22, 2013
    Publication date: June 30, 2016
    Inventors: Kensuke MIYAKE, Atsuo KANNO, Yuji MOTOI, Masahiro ONJI